Corbus Pharmaceuticals Holdings (LTS:0SZI) EBIT : $-37.81 Mil (TTM As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Corbus Pharmaceuticals Holdings EBIT?

Corbus Pharmaceuticals Holdings's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-9.62 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-37.81 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Corbus Pharmaceuticals Holdings's annualized ROC % for the quarter that ended in Mar. 2024 was -174.86%. Corbus Pharmaceuticals Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -999.92%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Corbus Pharmaceuticals Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -9.75%.

Corbus Pharmaceuticals Holdings EBIT Historical Data

The historical data trend for Corbus Pharmaceuticals Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corbus Pharmaceuticals Holdings EBIT Chart

Corbus Pharmaceuticals Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-77.11

-122.81

-55.99

-34.84

-45.08

Corbus Pharmaceuticals Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial															-17.30	-8.19	-9.29	-10.71	-9.62

Competitive Comparison of Corbus Pharmaceuticals Holdings's EBIT

For the Biotechnology subindustry, Corbus Pharmaceuticals Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Corbus Pharmaceuticals Holdings's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corbus Pharmaceuticals Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Corbus Pharmaceuticals Holdings's EV-to-EBIT falls into.

Corbus Pharmaceuticals Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-37.81 Mil.

Corbus Pharmaceuticals Holdings (LTS:0SZI) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Corbus Pharmaceuticals Holdings's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-38.492 * ( 1 - 0% )	/	( (24.736	+	19.291)	/ 2 )
=	-38.492	/	22.0135
=	-174.86 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	28.272	-	11.884	-	( 20.906	-	max(0, 31.894	-	23.546	+	20.906	))
=	24.736

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	125.744	-	10.68	-	( 120.103	-	max(0, 25.923	-	121.696	+	120.103	))
=	19.291

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Corbus Pharmaceuticals Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-38.492	/	( ( (4.036 + max(-11.608, 0))	+	(3.663 + max(-9.898, 0)) )	/	2 )
=	-38.492	/	( ( 4.036	+	3.663 )	/	2 )
=	-38.492	/	3.8495
=	-999.92 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	2.64)	-	(11.884	+	0	+	2.364)
=	-11.608

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	1.593)	-	(10.68	+	0	+	0.811)
=	-9.898

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Corbus Pharmaceuticals Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	-37.814	/	387.917
	=	-9.75 %

Corbus Pharmaceuticals Holdings EBIT Related Terms

Thank you for viewing the detailed overview of Corbus Pharmaceuticals Holdings's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Corbus Pharmaceuticals Holdings (LTS:0SZI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corbus Pharmaceuticals Holdings Inc (LTS:0SZI) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

CRBP:USA

Address

500 River Ridge Drive, Norwood, MA, USA, 02062

Website

https://www.corbuspharma.com

Corbus Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for endocannabinoid or immune systems. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. Corbus' internal development pipeline includes CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells.

Corbus Pharmaceuticals Holdings (LTS:0SZI) Headlines

No Headlines